On Friday May 21st at 10:30 AM ET, Jack Meehan, lead analyst Life Science Tools & Diagnostics, and Eric Percher, lead analyst Pharma Supply Chain, Pricing & Policy, hosted a joint 20-min call exploring their recent reports on biopharma end market growth and the outlook for specialty pharmacy growth 2021-2025, respectively.

Topics included:

• Comprehensive update on the biopharma end market through the lens of the supply chain – including the Life Science Tools, CROs and CDMOs, Distributors, Pharmacies and Payors/PBMs.
• Key data points used to monitor biopharma end market trends: Including FDA activity measures, clinical trial trends, the outlook for biopharma funding, and investment in COVID-19 vaccines.
• Our forecast for specialty pharmaceutical market growth 2021-2025 across 18therapeutic categories, detailing implications for biopharma and participants in the specialty pharmaceutical supply chain